Statins and Cancer-Related Mortality — Let's Work Together

A partir de données médicales portant sur 295 925 patients âgés d'au moins 40 ans et atteints d'un cancer diagnostiqué entre 1995 et 2007 (fin du suivi : décembre 2009), cette étude danoise évalue l'effet de la consommation de statines sur la mortalité par cancer (18 721 cas et 277 204 témoins)

Résumé en anglais

In this issue of the Journal, Nielsen et al. provide data suggesting that statin use in Denmark has caused a substantial decline in all-cause and cancer-related mortality. Collectively, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are the most commonly prescribed class of drugs worldwide, and after two and a half decades of use, this therapy has been credited with declines in cardiovascular events at the cost of some common side effects (myalgia and diabetes) and some that are rare (elevated liver enzyme levels and rhabdomyolysis). Previous studies focusing on statins and the incidence of cancer have provided only weak . . .